

PET CT Scan done on 25/11/2022 showed that lung metastases had progressed. Therefore, Stereotactic body radiotherapy (SBRT) in a dose of 56 Gy in 7 fractions was given till 27/12/2022. Also a repeat CanCertain sensitivity testing was performed on 25/12/2022. The cells retained their sensitivity to Doxorubicin and Epirubicin, Paclitaxel and Docetaxel along with Etoposide, Cyclophosphamide, Vincristine, and Vinorelbine, while were resistant to Gemcitabine. PD-L1 by was still negative. In accordance with the CanCertain suggested regimen, the patient was continued on metronomic therapy along with SBRT to the right lung. PET CT scan done on 27/3/2023 showed progressive disease.

Although the treatment options included chemotherapy/targeted therapy/immunotherapy, the CanCertain assay showed the following results. The test was repeated and showed that immunotherapy drugs (Atezolizumab and Nivolumab) are not effective in this case. Epirubicin, Paclitaxel and Gefitinib are mildly effective whereas Docetaxel and Palbociclib are very effective.

Interestingly, as per the latest scan, the patient is responding to the CanCertain suggested regimen.